What is biopharmaceutics and how does it fit into the field of pharmaceutical drug development? Quotient Sciences Dr. Vanessa Zann, Senior Drug Development Consultant speaks with Pharmaceutical Technology. Dr. Zann's article examines biopharmaceutics which looks at the fundamental properties of…

Poor solubility is becoming increasingly prevalent in drug pipelines. Infact, across the pharmaceutical industry, about 70 percent of drugs that enter development possess insufficient aqueous solubility for adequate and consistent gastrointestinal absorption. In a recent article with Drug Development &…

Quotient Sciences, the drug development and manufacturing accelerator, today announced that it has grown the workforce at its Alnwick, UK, facility by 20% over the past 2 years. The Alnwick site’s growth has been fueled by its attractive location, variety…

Evecxia Therapeutics, Inc. announced favorable safety, tolerability, pharmacokinetic, and pharmacodynamic data from a double-blind, placebo-controlled Phase 1, a two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram. The Company further…

Crinetics Pharmaceuticals, a pharmaceutical company that develops therapies for rare endocrine diseases, and Quotient Sciences, a drug development and manufacturing accelerator, have announced a partnership to support Crinetics’ CRN04894 pediatric program. The partnership will utilize Quotient Sciences’ unique Translational Pharmaceutics®…

Quotient Sciences, the drug development and manufacturing accelerator, announced a £6.3 million-pound investment in its recently acquired manufacturing facility in Alnwick, U.K. The investment will significantly expand Quotient’s drug substance manufacturing capability and will create 80 new jobs over the…